Effects of simvastatin on left ventricular hypertrophy and function in rats with aortic stenosis

Acta Pharmacologica Sinica

Volumn 20, Issue 4, 1999, Pages 345-348

  Luo, Jian Dong ^a   Zhang, Wei Wen ^a   Zhang, Gui Ping ^a   Liu, Xi Hong ^a   Guan, Jin Xia ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Abdominal aorta; Heart function tests; Hydroxyproline; Left ventricular hypertrophy; Simvastatin; Vascular stenosis

Indexed keywords

HYDROXYPROLINE; SIMVASTATIN;

ANIMAL EXPERIMENT; AORTA STENOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEART WEIGHT; MALE; NONHUMAN; RAT;

ANIMALS; AORTIC VALVE STENOSIS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYPROLINE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIUM; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; VENTRICULAR FUNCTION, LEFT;

EID: 0032954146     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
2. Grünler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1991; 1212: 259-77.
3. Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990; 4: 3319-28.
4. Glomset JA, Gelb MH, Famsworth CC. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem Sci 1990; 15: 139-42.
5. Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1991; 10: 181-205.
6. Thorburn A, Thorburn J, Chen SY, Powers S, Shubeita HE, Feramisco JR, et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 1993; 268:2244-9.
7. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 1995; 270: 23173-8.
8. Prockop DJ, Udenfriend S. A specific method for the analysis of hydroxyproline in tissues and urine. Anal Biochem 1960; 1: 228-39.
9. Lai YL, Chen CF, Chien CT, Shiao HL, Thacker AA, Zhang HQ. Capsaicin pretreatment attenuated chronic hypoxic pulmonary hypertension. Respir Physiol 1995; 99: 283-9.
10. Raiteri M, Arnaboldi L, McGeady P, Gelb MH, Verri D, Tagliabue C, et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997; 281: 1144-53.
11. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darbell J, editors. Molecular cell biology. 3nd ed. New York : Scientific American Books; 1995. p 887-97.
12. Yamazaki T, Yazaki Y. Is there major involvement of the renin-angiotensin system in cardiac hypertrophy. Circ Res 1997; 81: 639-42.
13. Weinberg EO, Lee MA, Weigner M, Lindpaintner K, Bishop SP, Benedict CR, et al. Angiotensin ATI receptor inhibition; effects on hypertrophic remodeling and ACE expression in rats with pressureoverload hypertrophy due to ascending aortic stenosis. Circulation 1997; 95: 1592-1600.
14. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 1996; 119: 1269-75.
15. + antiporter (NHE-1) gene expression during growth, hypertrophy and proliferation of the rabbit cardiovascular system. J Mol Cell Cardiol 1995; 27: 729-42.